NEW YORK (GenomeWeb News) – The European Union plans to fund new research seeking to establish the clinical utility of epigenetic biomarkers for blood-based diseases under its Blueprint consortium program, a €30 million ($39.8 million) effort focused on advancing hematopoietic biomarkers.

The Blueprint program is supporting several projects to speed the development, validation, and use of epigenetic biomarkers in treating diseases such as myeloid and lymphoblastic leukemias, myelodysplastic syndromes, lymphomas, and type 1 diabetes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

The NIH has issued a preliminary guidance for newborn dried blood spot research.